Peptide purity vs identity: HPLC and mass spec explained

Peptide HPLC purity tells you what share of the material in a sample is the main peptide; mass spectrometry tells you whether that main peptide has the right molecular mass. They answer two different questions, purity and identity, and neither one can replace the other. A sample can show a single clean HPLC peak and still be the wrong molecule, and a sample can show the right mass while carrying a large load of impurities. If you want a step-by-step check of a certificate itself (batch numbers, lab details, red flags), use our companion guide on how to verify a peptide COA; this page covers the science behind the numbers on it.

HPLC and mass spec at a glance

How HPLC measures purity

High-performance liquid chromatography pushes a dissolved sample through a packed column. In reversed-phase HPLC, the most common method for peptides, molecules separate by how strongly they stick to the hydrophobic column material, so the target peptide and its near relatives leave the column at different times. A UV detector records each one as a peak. Purity is reported as the main peak's area divided by the total area of all peaks. A 2024 study of synthetic peptide pools, for example, estimated purity from relative UV peak areas at 214 nm.

A 2014 BioPharm International review of control strategies for synthetic peptide APIs describes HPLC as the usual purity method and says it should separate impurities from starting materials, the manufacturing process and degradation. HPLC can also support identity, but only by comparing retention time with an authentic reference standard; when the two are run together they should give a single peak.

The weakness is overlap. If an impurity leaves the column at the same time as the main peptide, it hides inside the main peak and the purity figure looks better than it is. The 2024 study noted that overlapping peaks made UV purity less accurate for some species. Hence the call for orthogonal methods: a second separation on a different principle, such as ion exchange.

How mass spectrometry confirms identity

A mass spectrometer turns molecules into charged ions and measures their mass-to-charge ratio, from which the molecular mass is calculated. For identity, the observed mass is compared with the theoretical mass from the intended sequence. The 2014 review describes a check of the monoisotopic mass within ±1.0 mass unit, noting that peptides above about 2 kDa may need high-resolution MS or average mass. Tandem MS (MS/MS) fragments the peptide so the sequence can be read.

Mass spec is also the main tool for naming impurities. A mass shift points to a specific change: in the 2024 study, shifts of −17 and −18 Da helped identify cyclization products, and methionine oxidation was seen in every methionine-containing peptide.

Its key limitation is that molecules with the same mass look the same. The 2014 review states that MS cannot distinguish isomers such as leucine and isoleucine, or D- and L-amino acid substitutions, and the 2024 study noted that epimerized and iso forms are not readily identified by MS. Nor does a correct mass show how much of the sample is the target.

Why you need both, plus LC-MS

A batch could hold the wrong peptide, one residue short, and still give a sharp HPLC peak at 98%; only MS would catch that. Or it could hold the right peptide at 80% among deletion sequences; MS would confirm the mass, and only HPLC would show the impurities. LC-MS joins the two: the HPLC separates the peaks and the mass spectrometer identifies each one.

Regulators build this into their expectations. A Saudi FDA guideline on synthetic peptide quality, in force from 29 October 2026, says at least two orthogonal methods should be used for identification, naming RP-HPLC and MS, with amino acid analysis, peptide mapping, NMR and MS/MS as alternatives. It lists peptide-related impurities such as deletions, insertions, truncations, oxidation and deamidation, and recommends LC-HRMS or LC-MS/MS to characterize them. In the US, an FDA presentation on generic synthetic peptide applications says each peptide-related impurity at or above 0.10% should be identified, that there should be no new peptide-related impurity above 0.5% compared with the reference product, and recommends UHPLC-HRMS/MS for peak identity and peak purity. These figures apply to drug applications, not research-grade material.

Purity is not peptide content

One of the most common misreadings of a COA is treating HPLC purity as the amount of peptide in the vial. HPLC purity only compares peptide-like peaks with each other. The powder also contains water and counterions left from synthesis and purification, commonly acetate, chloride or trifluoroacetate (TFA). The 2014 review treats peptide content (assay) as a separate measurement correcting for counterion and water, using methods such as amino acid analysis, nitrogen content or quantitative NMR. A sample can therefore be 99% pure and still be well under 100% peptide by weight.

At the bench, in-vitro stock molarity depends on the actual peptide weighed, so use net peptide content where given and the molecular weight of the stated salt form. Our peptide calculator handles the math.

What a stronger certificate looks like

• An HPLC chromatogram with method and wavelength, not just a number.
• A mass spectrum with the observed and theoretical mass shown side by side.
• Net peptide content or assay reported separately from purity, ideally with the counterion named.
• A batch or lot number that matches the vial; see how to verify a peptide COA.

For risks that testing cannot remove, read synthetic peptide safety risks, and for background on the molecules themselves, what are peptides?

Frequently asked questions

Sources

1. Verlander and Rode, Control strategies for synthetic therapeutic peptide APIs, Part I: analytical consideration, BioPharm International (1 March 2014)
2. Saudi Food and Drug Authority: guideline on the quality of synthetic peptides, DS-G-143 v1.0 (issued 29 September 2026)
3. FDA CDER (Yili Li): Common deficiencies in comparative peptide impurity profile studies, SBIA 2022 (20 September 2022)
4. Bosc-Bierne and Weller, Investigation of impurities in peptide pools, Preprints.org (10 December 2024)